Verus Capital Partners’s Adicet Bio ACET Stock Holding History

Verus Capital Partners’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-4	Closed	-$1K	–	1471
2019 Q4	$1K	Buy	+4	New	+$2.02K	﹤0.01%	1461

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ruffer LLP London, United Kingdom $2.44B AUM 44.75% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Verus Capital Partners's ACET Position: Q1 2020 in Review

Verus Capital Partners sold out of Adicet Bio (ACET) in Q1 2020, closing a stake of 4 shares — an estimated $1K sold.

Verus Capital Partners first reported a position in ACET in Q4 2019 and held it in 1 quarter. The position peaked at $1K in Q4 2019. 51 funds tracked by Wall St. Rank hold ACET as of Q1 2020.

Verus Capital Partners reported no remaining Adicet Bio position as of Q1 2020 after selling out during the quarter.
Verus Capital Partners sold 4 Adicet Bio shares in Q1 2020, an estimated $1K.
Verus Capital Partners first reported a position in Adicet Bio in Q4 2019 and held it in 1 quarter.
Verus Capital Partners's Adicet Bio position peaked at $1K in Q4 2019.
51 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.